Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma

Elena Bernasconi, Eugenio Gaudio, Pascale Lejeune, Chiara Tarantelli, Luciano Cascione, Ivo Kwee, Filippo Spriano, Andrea Rinaldi, Afua A. Mensah, Elaine Y. L. Chung, Anastasios Stathis, Stephan Siegel, Norbert Schmees, Matthias Ocker, Emanuele Zucca, Bernard Haendler, Francesco Bertoni

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The epigenome is often deregulated in cancer and treatment with inhibitors of bromodomain and extra-terminal proteins, the readers of epigenetic acetylation marks, represents a novel therapeutic approach. Here, we have characterized the anti-tumour activity of the novel bromodomain and extra-terminal (BET) inhibitor BAY 1238097 in preclinical lymphoma models. BAY 1238097 showed anti-proliferative activity in a large panel of lymphoma-derived cell lines, with a median 50% inhibitory concentration between 70 and 208 nmol/l. The compound showed strong anti-tumour efficacy in vivo as a single agent in two diffuse large B cell lymphoma models. Gene expression profiling showed BAY 1238097 targeted the NFKB/TLR/JAK/STAT signalling pathways, MYC and E2F1-regulated genes, cell cycle regulation and chromatin structure. The gene expression profiling signatures also highly overlapped with the signatures obtained with other BET Bromodomain inhibitors and partially overlapped with HDAC-inhibitors, mTOR inhibitors and demethylating agents. Notably, BAY 1238097 presented in vitro synergism with EZH2, mTOR and BTK inhibitors. In conclusion, the BET inhibitor BAY 1238097 presented promising anti-lymphoma preclinical activity in vitro and in vivo, mediated by the interference with biological processes driving the lymphoma cells. Our data also indicate the use of combination schemes targeting EZH2, mTOR and BTK alongside BET bromodomains.

Original languageEnglish (US)
Pages (from-to)936-948
Number of pages13
JournalBritish Journal of Haematology
Volume178
Issue number6
DOIs
StatePublished - Sep 1 2017
Externally publishedYes

Fingerprint

Lymphoma
Gene Expression Profiling
Biological Phenomena
cdc Genes
Neoplasms
Histone Deacetylase Inhibitors
Lymphoma, Large B-Cell, Diffuse
Acetylation
Transcriptome
Epigenomics
Inhibitory Concentration 50
Chromatin
Cell Line
Proteins
Therapeutics

Keywords

  • BET Bromodomain
  • Epigenetics
  • EZH2
  • ibrutinib
  • Lymphomas
  • mTOR

ASJC Scopus subject areas

  • Hematology

Cite this

Bernasconi, E., Gaudio, E., Lejeune, P., Tarantelli, C., Cascione, L., Kwee, I., ... Bertoni, F. (2017). Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. British Journal of Haematology, 178(6), 936-948. https://doi.org/10.1111/bjh.14803

Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. / Bernasconi, Elena; Gaudio, Eugenio; Lejeune, Pascale; Tarantelli, Chiara; Cascione, Luciano; Kwee, Ivo; Spriano, Filippo; Rinaldi, Andrea; Mensah, Afua A.; Chung, Elaine Y. L.; Stathis, Anastasios; Siegel, Stephan; Schmees, Norbert; Ocker, Matthias; Zucca, Emanuele; Haendler, Bernard; Bertoni, Francesco.

In: British Journal of Haematology, Vol. 178, No. 6, 01.09.2017, p. 936-948.

Research output: Contribution to journalArticle

Bernasconi, E, Gaudio, E, Lejeune, P, Tarantelli, C, Cascione, L, Kwee, I, Spriano, F, Rinaldi, A, Mensah, AA, Chung, EYL, Stathis, A, Siegel, S, Schmees, N, Ocker, M, Zucca, E, Haendler, B & Bertoni, F 2017, 'Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma', British Journal of Haematology, vol. 178, no. 6, pp. 936-948. https://doi.org/10.1111/bjh.14803
Bernasconi, Elena ; Gaudio, Eugenio ; Lejeune, Pascale ; Tarantelli, Chiara ; Cascione, Luciano ; Kwee, Ivo ; Spriano, Filippo ; Rinaldi, Andrea ; Mensah, Afua A. ; Chung, Elaine Y. L. ; Stathis, Anastasios ; Siegel, Stephan ; Schmees, Norbert ; Ocker, Matthias ; Zucca, Emanuele ; Haendler, Bernard ; Bertoni, Francesco. / Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. In: British Journal of Haematology. 2017 ; Vol. 178, No. 6. pp. 936-948.
@article{1c619b1f459d46f0b130cba74baaa908,
title = "Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma",
abstract = "The epigenome is often deregulated in cancer and treatment with inhibitors of bromodomain and extra-terminal proteins, the readers of epigenetic acetylation marks, represents a novel therapeutic approach. Here, we have characterized the anti-tumour activity of the novel bromodomain and extra-terminal (BET) inhibitor BAY 1238097 in preclinical lymphoma models. BAY 1238097 showed anti-proliferative activity in a large panel of lymphoma-derived cell lines, with a median 50{\%} inhibitory concentration between 70 and 208 nmol/l. The compound showed strong anti-tumour efficacy in vivo as a single agent in two diffuse large B cell lymphoma models. Gene expression profiling showed BAY 1238097 targeted the NFKB/TLR/JAK/STAT signalling pathways, MYC and E2F1-regulated genes, cell cycle regulation and chromatin structure. The gene expression profiling signatures also highly overlapped with the signatures obtained with other BET Bromodomain inhibitors and partially overlapped with HDAC-inhibitors, mTOR inhibitors and demethylating agents. Notably, BAY 1238097 presented in vitro synergism with EZH2, mTOR and BTK inhibitors. In conclusion, the BET inhibitor BAY 1238097 presented promising anti-lymphoma preclinical activity in vitro and in vivo, mediated by the interference with biological processes driving the lymphoma cells. Our data also indicate the use of combination schemes targeting EZH2, mTOR and BTK alongside BET bromodomains.",
keywords = "BET Bromodomain, Epigenetics, EZH2, ibrutinib, Lymphomas, mTOR",
author = "Elena Bernasconi and Eugenio Gaudio and Pascale Lejeune and Chiara Tarantelli and Luciano Cascione and Ivo Kwee and Filippo Spriano and Andrea Rinaldi and Mensah, {Afua A.} and Chung, {Elaine Y. L.} and Anastasios Stathis and Stephan Siegel and Norbert Schmees and Matthias Ocker and Emanuele Zucca and Bernard Haendler and Francesco Bertoni",
year = "2017",
month = "9",
day = "1",
doi = "10.1111/bjh.14803",
language = "English (US)",
volume = "178",
pages = "936--948",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma

AU - Bernasconi, Elena

AU - Gaudio, Eugenio

AU - Lejeune, Pascale

AU - Tarantelli, Chiara

AU - Cascione, Luciano

AU - Kwee, Ivo

AU - Spriano, Filippo

AU - Rinaldi, Andrea

AU - Mensah, Afua A.

AU - Chung, Elaine Y. L.

AU - Stathis, Anastasios

AU - Siegel, Stephan

AU - Schmees, Norbert

AU - Ocker, Matthias

AU - Zucca, Emanuele

AU - Haendler, Bernard

AU - Bertoni, Francesco

PY - 2017/9/1

Y1 - 2017/9/1

N2 - The epigenome is often deregulated in cancer and treatment with inhibitors of bromodomain and extra-terminal proteins, the readers of epigenetic acetylation marks, represents a novel therapeutic approach. Here, we have characterized the anti-tumour activity of the novel bromodomain and extra-terminal (BET) inhibitor BAY 1238097 in preclinical lymphoma models. BAY 1238097 showed anti-proliferative activity in a large panel of lymphoma-derived cell lines, with a median 50% inhibitory concentration between 70 and 208 nmol/l. The compound showed strong anti-tumour efficacy in vivo as a single agent in two diffuse large B cell lymphoma models. Gene expression profiling showed BAY 1238097 targeted the NFKB/TLR/JAK/STAT signalling pathways, MYC and E2F1-regulated genes, cell cycle regulation and chromatin structure. The gene expression profiling signatures also highly overlapped with the signatures obtained with other BET Bromodomain inhibitors and partially overlapped with HDAC-inhibitors, mTOR inhibitors and demethylating agents. Notably, BAY 1238097 presented in vitro synergism with EZH2, mTOR and BTK inhibitors. In conclusion, the BET inhibitor BAY 1238097 presented promising anti-lymphoma preclinical activity in vitro and in vivo, mediated by the interference with biological processes driving the lymphoma cells. Our data also indicate the use of combination schemes targeting EZH2, mTOR and BTK alongside BET bromodomains.

AB - The epigenome is often deregulated in cancer and treatment with inhibitors of bromodomain and extra-terminal proteins, the readers of epigenetic acetylation marks, represents a novel therapeutic approach. Here, we have characterized the anti-tumour activity of the novel bromodomain and extra-terminal (BET) inhibitor BAY 1238097 in preclinical lymphoma models. BAY 1238097 showed anti-proliferative activity in a large panel of lymphoma-derived cell lines, with a median 50% inhibitory concentration between 70 and 208 nmol/l. The compound showed strong anti-tumour efficacy in vivo as a single agent in two diffuse large B cell lymphoma models. Gene expression profiling showed BAY 1238097 targeted the NFKB/TLR/JAK/STAT signalling pathways, MYC and E2F1-regulated genes, cell cycle regulation and chromatin structure. The gene expression profiling signatures also highly overlapped with the signatures obtained with other BET Bromodomain inhibitors and partially overlapped with HDAC-inhibitors, mTOR inhibitors and demethylating agents. Notably, BAY 1238097 presented in vitro synergism with EZH2, mTOR and BTK inhibitors. In conclusion, the BET inhibitor BAY 1238097 presented promising anti-lymphoma preclinical activity in vitro and in vivo, mediated by the interference with biological processes driving the lymphoma cells. Our data also indicate the use of combination schemes targeting EZH2, mTOR and BTK alongside BET bromodomains.

KW - BET Bromodomain

KW - Epigenetics

KW - EZH2

KW - ibrutinib

KW - Lymphomas

KW - mTOR

UR - http://www.scopus.com/inward/record.url?scp=85021318190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021318190&partnerID=8YFLogxK

U2 - 10.1111/bjh.14803

DO - 10.1111/bjh.14803

M3 - Article

C2 - 28653353

AN - SCOPUS:85021318190

VL - 178

SP - 936

EP - 948

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -